Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ontamalimab Induction Therapy in Moderate to Severe Crohn's Disease
NCT03559517Phase 3Terminated
- Sponsor
- Takeda
- Start
- Aug 2018
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of ontamalimab in Crohn's disease, sponsored by Takeda. Started Aug 2018; status: terminated.
02
Drugs
ontamalimab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03559517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03559517.